Cardiovascular Risk and Fatty Liver Disease
A/Prof William Kemp
Fatty liver disease is the canary in the coalmine when it comes to adverse cardiovascular events. So says hepatologist, Associate Professor William Kemp who in this talk will be discussing how early identification, assessment and treatment of fatty liver disease can not only prevent the development of liver fibrosis and cirrhosis, but can also address a key risk factor for future cardiovascular disease. He will also provide an update on the latest recommendations on who best to screen, how to screen, how to assess severity and how to manage fatty liver disease, including when to refer.
Importance of Early & Effective Treatment of Mild to Moderate Acne
Dr Ryan De Cruz
Acne continues to cause distress and depression in many young people, not helped by the fact they are being bombarded by advice and misinformation on social media. In this talk, dermatologist Dr Ryan de Cruz discusses the evidence-based recommendations for assessing and managing mild-to-moderate acne including both over-the-counter and prescription products. He will also provide information about the various factors in both the patient and the acne that help determine the most appropriate treatment option for that individual.
SGLT2s and Renal Protection
Prof Merlin Thomas
Screening for CKD should be a priority among at-risk patients as this condition is common, usually silent and a major risk factor for early mortality. So says clinician scientist, Professor Merlin Thomas, who, in this talk, will present data on the prevalence and significance of CKD as well as providing details on who to screen, how to screen and how to mitigate the risk of further progression and complications. In particular, he will discuss the pivotal role of SGLT-2 inhibitors in CKD and how early introduction can help avoid not only future renal failure but also cardiovascular adverse events.
CV Medications – Practical Strategies to Improve Compliance
Dr Adam Nelson
In almost every area of preventive medicine, patient adherence to medication, or more precisely lack of adherence is a major barrier to success. Cardioprotective medications are a case in point. In this very real-world talk, Dr Adam Nelson will discuss the challenges presented by patient adherence in cardiovascular medicine, and importantly what has been proven to be effective in improving adherence rates, including the use of easily-accessible digital tools. He will also detail how just a small improvement in patient compliance in this area of medicine could and would have a major impact on population health outcomes.
Cardiovascular Risk and Fatty Liver Disease
A/Prof William Kemp
Fatty liver disease is the canary in the coalmine when it comes to adverse cardiovascular events. So says hepatologist, Associate Professor William Kemp who in this talk will be discussing how early identification, assessment and treatment of fatty liver disease can not only prevent the development of liver fibrosis and cirrhosis, but can also address a key risk factor for future cardiovascular disease. He will also provide an update on the latest recommendations on who best to screen, how to screen, how to assess severity and how to manage fatty liver disease, including when to refer.
Importance of Early & Effective Treatment of Mild to Moderate Acne
Dr Ryan De Cruz
Acne continues to cause distress and depression in many young people, not helped by the fact they are being bombarded by advice and misinformation on social media. In this talk, dermatologist Dr Ryan de Cruz discusses the evidence-based recommendations for assessing and managing mild-to-moderate acne including both over-the-counter and prescription products. He will also provide information about the various factors in both the patient and the acne that help determine the most appropriate treatment option for that individual.
SGLT2s and Renal Protection
Prof Merlin Thomas
Screening for CKD should be a priority among at-risk patients as this condition is common, usually silent and a major risk factor for early mortality. So says clinician scientist, Professor Merlin Thomas, who, in this talk, will present data on the prevalence and significance of CKD as well as providing details on who to screen, how to screen and how to mitigate the risk of further progression and complications. In particular, he will discuss the pivotal role of SGLT-2 inhibitors in CKD and how early introduction can help avoid not only future renal failure but also cardiovascular adverse events.
CV Medications – Practical Strategies to Improve Compliance
Dr Adam Nelson
In almost every area of preventive medicine, patient adherence to medication, or more precisely lack of adherence is a major barrier to success. Cardioprotective medications are a case in point. In this very real-world talk, Dr Adam Nelson will discuss the challenges presented by patient adherence in cardiovascular medicine, and importantly what has been proven to be effective in improving adherence rates, including the use of easily-accessible digital tools. He will also detail how just a small improvement in patient compliance in this area of medicine could and would have a major impact on population health outcomes.
